IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT06623669 (MORPH-III) pour Douleur chronique, Arthrose, Obesity and Overweight, Inactivity est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
A Mobile Intervention to Reduce Pain and Improve Health-III (MORPH-III)
The overarching goal of the proposed Stage II "mobile intervention to reduce pain and improve health-III (MORPH-III)" is to establish the efficacy of the intervention for enhancing physical activity via steps (primary), and for reducing pain interference and body weight while enhancing physical function (secondary) among older adults with chronic knee or hip osteoarthritic (OA) pain. The investigators will recruit 200 older adults with knee or hip osteoarthritic pain to engage in a 6-month remotely delivered intervention comprising weekly group or individual intervention meetings plus brief individual goal-setting coaching calls. This will be followed by a 12-month no-contact maintenance period, where participants will attempt to sustain behavioral goals on their own.
The Specific Aims are:
Specific Aim 1: To examine the impact of MORPH on ActivPAL-assessed daily steps relative to an enhanced usual care control. Hypotheses: MORPH will significantly increase steps relative to control at month 6.
Specific Aim 2: To examine the impact of MORPH on pain interference, change in body weight, and physical function relative to the enhanced usual care control. Hypotheses: MORPH will result in significant reductions in pain interference and body weight and improvement in physical function relative to control at month 6.
Exploratory Aims: Aim 1: To investigate the impact of the MORPH intervention on steps, weight change, pain interference, and physical function at month 18. Aim 2: If the MORPH intervention results in reduced pain interference at 6 and/or 18 months, the investigators will examine the extent to which 6-month change in steps, weight, pain self-efficacy, and catastrophizing mediate change in interference at 6 and/or 18 months.
A Mobile Intervention to Reduce Pain and Improve Health-III
- MORPH-III
- IRB00025649
- R01AG082777 (Subvention/contrat NIH (É.-U.))
Randomized Trial
Physical Activity
Weight Loss
Aging
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalMORPH MORPH participants will attend one weekly group-mediated session alongside a group of their peers plus individual coaching calls. Participants will aim to increase daily steps by moving often throughout the day, using an activity monitor and mHealth app to view feedback and set goals. Participants will also aim to weight via healthy eating while reducing daily calories by \~400kcal/day below weight maintenance needs to achieve approximately 6% weight loss in 6 months and 10% over 18 months. | MORPH A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors. |
Comparateur actifMeasurement Only Measurement-only participants will receive an activity monitor and wireless weight scale to account for the effect of these self-monitoring technologies and activity behavior. | Measurement ONLY This intervention entails receipt of a body weight scale and wearable activity monitor. |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Daily steps | Daily steps measured over one week via the ActivPAL accelerometer | Baseline, after 6 months of intervention, after 18 months of intervention |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Pain Interference | Measured via questionnaire: the Patient-Reported Outcomes Measurement Information System (PROMIS) 8-item pain interference scale, which produces a t-score such that the population mean is a 50 with a standard deviation of 10; higher scores indicate higher interference. | Baseline, after 6 months of intervention, after 18 months of intervention |
Body weight | Measured via the BodyTrace wireless body weight scale | From the start of the intervention through month 18. |
30-second chair stand | Measured via in-home chair stand task. | Baseline, after 6 months of intervention, after 18 months of intervention |
Gait speed | Measured via in-home test: 4-meter habitual gait speed | Baseline, after 6 months of intervention, after 18 months of intervention |
- Aged 65+ years
- Body mass index of 30-45 kg/m2 or >45 kg/m2 with physician's approval
- No loss or gain of more than 5% body mass in previous 6 months
- Presence of knee or hip osteoarthritis as ascertained via the Roux questionnaire
- Independently living
- Low active (i.e., not participating in regular resistance training and/or >20 mins/day of aerobic exercise on more than 2 days/week in past 3 months as ascertained via a modified CHAMPS questionnaire)
- Have no contraindication for safe and optimal participation in exercise based on EASY screening
- Not currently using a weight loss medication
- Approved for participation by medical director
- Willing to provide informed consent and agree to all study procedures and assessments.
- Reside in skilled nursing facility, rehab or assisted living environment
- History of pharmacologic treatment for a psychiatric disorder other than depression/anxiety within past year
- Current untreated and/or unstable clinical depression or anxiety (Patient Health Questionnaire (PHQ-9) >15)
- Hospitalization for psychiatric event within past year prior to screening
- History of mild cognitive impairment or dementia
- Cognitive impairment (<32) on Modified Telephone Interview for Cognitive Status survey (TICS-M)
- Hearing or visual impairment that would preclude use of the videoconferencing software
- Severe arthritis or other musculoskeletal disorder that is a contraindication for safe walking
- Presently undergoing treatment for orthopedic fracture
- Currently using a weight loss medication
- Contraindication based on EASY screening without physician approval.
- Joint replacement or other orthopedic surgery in past 6 months
- Joint replacement or other orthopedic surgery planned in next 18 months
- Have a diagnosis of uncontrolled hypertension; current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease other than asthma or COPD, any disease requiring oxygen use, neurological or hematological disease; cancer requiring current treatment, except non-melanoma skin cancers; kidney failure requiring dialysis; have a Katz ADL disability; or engage in heavy alcohol use >14 drinks/week.
- Current participation in other research study with a prospective intervention
- Unable/unwilling to commit to study protocol, including random assignment and use of technology tools
- Unable/unwilling to attend three virtual testing appointments
Université Wake Forest325 essais cliniques actifs à explorer
Université Duke545 essais cliniques actifs à explorer
- 🏛️National Institute on Aging (NIA)
North Carolina